Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

RVC collaborates with UCB on bone overgrowth research
"It is an incredible opportunity to advance our understanding of this ultra-rare bone disease" - Dr Tim Dreyer.

The project will explore Sclerosteosis and Ankylosing Spondylitis.

The Royal Veterinary College (RVC) is collaborating with the biopharmaceutical company UCB to research diseases of excessive bone formation.

In a new multi-year research project, the organisations will investigate therapeutic options and mechanisms of disease progression in two severe bone diseases characterised by bone overgrowth - sclerosteosis, and the inflammatory condition ankylosing spondylitis.

Dr Scott Roberts, senior lecturer in translational skeletal research at the RVC, said: “I am excited to be working closely with UCB and RVC colleagues to investigate why pathological bone is formed in ankylosing spondylitis and how excessive bone formation can be controlled in sclerosteosis. 

“This research interaction will allow us to further our understanding of these specific diseases, with our accrued knowledge also likely to be applicable to other conditions of altered bone metabolism.”

Sclerosteosis is an ultra-rare genetic bone disease, in which patients experience widespread bone overgrowth as a result of the loss of sclerostin expression. The overgrowth of bone can result in severe, and even fatal, pressure on the brain due to increases in skull thickness. This can only be resolved temporarily through major surgery.

Ankylosing spondylitis patients also experience bone overgrowth, occurring most commonly in the spine. This overgrowth can lead to pain, bone fusion and deformity. The major change of structural tissue damage can result in permanent disability. 

Over the course of three years, the team of researchers led by Dr Scott Roberts, will test potential new therapeutic options in preclinical models for sclerosteosis. Whilst ankylosing spondylitis already has approved therapeutics, the team will be researching why this bone forms using specialised disease models via human stem cells. 

Dr Tim Dreyer, postdoctoral researcher and sclerosteosis patient, commented on the new collaboration: “As a patient myself, I am thrilled to be part of a collaboration that aims to potentially develop a therapeutic for Sclerosteosis. 

“It is an incredible opportunity to advance our understanding of this ultra-rare bone disease, whilst providing hope for a small group of patients and their families.”

Senior vice president and head of discovery science at UCB, Dr Alistair Henry, added: “We are delighted to partner with the RVC on this important project to better understand disease progression in these two conditions. 

“Although very different diseases, both conditions have a painful and progressive impact on those living with them and we hope this project may pave the way for treatment to improve people’s lives.”

 

Image (C) Royal Veterinary College

Become a member or log in to add this story to your CPD history

Vets launch new podcast for pet owners

News Story 1
 Two independent vets have launched a podcast to help owners strengthen their bond with pets. Dr Maggie Roberts and Dr Vanessa Howie, who have worked in both veterinary practice and major charities, are keen to use their experience to enable people to give pets a better life.

The venture, called Vets Talking Pets, provides advice and information on a range of topics, including how to select a suitable pet, where to obtain them and how to get the best out of your vet. Maggie and Vanessa will also discuss sensitive subjects, including end-of-life care, raw food diets and the cost of veterinary care.

The podcast can be found on all the usual podcast sites, including Podbean, Apple, Amazon Music and YouTube. 

Click here for more...
News Shorts
VMD issues guidance on AVM-GSL packaging

The Veterinary Medicines Directorate (VMD) has shared advice on its requirements for medicines considered AVM-GSL.

The guidance explains the information that should be on the outer package, and sets out the typical maximum pack size for an AVM-GSL product. It also describes the user-friendly language, structure and phrases required on packaging and product leaflets.

AVM-GSL products do not require discussion between the purchaser and a veterinary professional. This means that clear product information is needed to support sales choices.

The information will be useful for submitting new products to the AVM-GSL category and lowering the distribution category of products from NFA-VPS to AVM-GSL.

The VMD's guidance can be accessed here.